

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



Notice Regarding Results of the 5th Ordinary General Meeting of Shareholders

TOKYO, June 25, 2026 – ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi) hereby announces the results of the exercise of voting rights for the matters resolved at the 5th Ordinary General Meeting of Shareholders held on June 24, 2026, as follows.

1. Results of Voting

All proposals submitted by the Company (Proposals 1 through 11) were approved and adopted as originally proposed by a majority of votes, while the shareholder proposal (Proposal 12) was rejected.

The Company acknowledges that it has received the understanding of its shareholders regarding its management policy. Under the new management team elected at this General Meeting of Shareholders, the Group will work as one to achieve sustainable growth and enhance corporate value over the medium to long term. The Company sincerely appreciates the continued support of its shareholders.

2. Results of Resolutions

	Results	Votes For	Votes Against	Abstentions	Invalid Votes	Approval Ratio
Proposal 1: Appropriation of Surplus						
	Approved	252,705	239	313	0	99.78
Proposal 2: Partial Amendments to the Articles of Incorporation						
	Approved	252,340	604	313	0	99.64
Proposal 3: Election of 10 Board Members (excluding Board Members who are Audit & Supervisory Committee Members)						
1. Takashi Yamaguchi	Approved	189,510	63,424	313	10	74.83
2. Sohta Yamaguchi	Approved	189,978	62,956	313	10	75.01
3. Atsushi Maruo	Approved	195,872	57,062	313	10	77.34
4. Maiko Mori	Approved	195,942	56,992	313	10	77.37
5. Fumiyoshi Yamaguchi	Approved	195,861	57,073	313	10	77.34
6. Minoru Awabayashi	Approved	195,535	57,399	313	10	77.21
7. Yasuji Enokido	Approved	195,854	57,080	313	10	77.33
8. Kanae Karita	Approved	195,942	56,992	313	10	77.37
9. Kiyoko Kato	Approved	195,918	57,016	313	10	77.36
10. James C. Feliciano	Approved	198,337	54,597	313	10	78.31

Proposal 4: Election of 3 Board Members who are Audit & Supervisory Committee Members						
1. Kunihiro Gunji	Approved	198,064	54,879	313	1	78.21
2. Takao Kimura	Approved	198,048	54,895	313	1	78.20
3. Koki Yamashita	Approved	198,338	54,605	313	1	78.31
Proposal 5: Election of 1 Substitute Board Member who is an Audit & Supervisory Committee Member (Takeru Nishino)						
	Approved	198,494	54,440	313	10	78.38
Proposal 6: Determination of the Amount of Remuneration for Board Members (excluding Board Members who are Audit & Supervisory Committee Members)						
	Approved	252,042	520	685	10	99.52
Proposal 7: Determination of the Amount of Remuneration for Board Members who are Audit & Supervisory Committee Members						
	Approved	252,047	515	685	10	99.52
Proposal 8: Revision of the Restricted Stock Compensation Plan for Board Members (excluding Board Members who are Audit & Supervisory Committee Members and Outside Directors)						
	Approved	251,784	1,150	313	10	99.42
Proposal 9: Determination of Remuneration for Outside Directors (excluding Board Members who are Audit & Supervisory Committee Members) to Grant Restricted Shares Thereto						
	Approved	245,661	7,273	313	10	97.00
Proposal 10: Election of Accounting Auditor						
	Approved	252,165	397	685	10	99.57
Proposal 11: Approval of Implementation of Countermeasures, in Light of the Current Situation in Which a Large-scale Purchase etc. by Dalton etc. Is Being Contemplated (Emergency Phase), in the Event that Dalton etc. Fail to Comply with the Company's Response Policies and Carry Out a Large-scale Purchase etc.						
	Approved	221,125	31,765	313	54	87.31
[Shareholder Proposal]						
Proposal 12: Election of 2 Board Members who are not Audit & Supervisory Committee Members						
1. James B. Rosenwald III	Rejected	55,878	196,921	313	145	22.06
2. Shiro Hayashi	Rejected	55,882	196,917	313	145	22.07

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp